Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study
复制标题

DOI:
10.1159/000491401
复制
发表时间:
2018-01-01
期刊:
影响因子:
3.2
通讯作者:
Sartorius, Alexander
Sartorius, Alexander
中科院分区:
心理学3区
文献类型:
--
作者:
Kranaster, Laura;Hoyer, Carolin;Sartorius, Alexander

文献摘要

被引文献

相似文献

背景资料:目前尚无基于脑脊液(CSF)的候选生物标志物被确定为电休克治疗(ECT)重度抑郁症患者的预后因素。方法:根据不同的基本假设,我们分析了神经变性标志物的基线CSF水平,(tau蛋白,β-淀粉样蛋白和神经颗粒蛋白),先天免疫系统的元素(白细胞介素[IL]-6,新蝶呤,可溶性CD 14,可溶性CD 163,迁移抑制因子和单核细胞趋化蛋白1),内源性大麻素,对12例抑郁症患者在ECT治疗前的鞘脂和Klotho进行比较,以确定与ECT临床抗抑郁反应的可能相关性。结果如下:可以观察到与抑郁症状减少的相关性,特别是神经变性的标志物和先天免疫系统的元素。在趋势水平上,在应答者和非应答者组之间发现了几种标志物的CSF水平差异。局限性:样本量较小,应答者和非应答者的分布不均匀。结论:这是首次对ECT抗抑郁疗效的CSF生物标志物进行研究,值得进一步研究ECT的机制和个性化抗抑郁治疗。
Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, -amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT inpatients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.